Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide

European Journal of Clinical Pharmacology

Volumn 34, Issue 2, 1988, Pages 157-163

  Back, D J ^a   Tjia, J ^a   Monig H ^b   Ohnhaus, E E ^b   Park, B K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

antipyrine; cimetidine; drug interaction; metabolite formation; pharmacokinetics; primaquine; selective inhibition; sulphaphenazole; tolbutamide

Indexed keywords

CIMETIDINE; CYTOCHROME P450; DRUG; PHENAZONE; PRIMAQUINE; SULFAPHENAZOLE; TOLBUTAMIDE;

BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; NORMAL VALUE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; URINE LEVEL;

ADULT; ANTIPYRINE; CIMETIDINE; FEMALE; HALF-LIFE; HUMAN; MALE; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; PRIMAQUINE; SULFAPHENAZOLE; SUPPORT, NON-U.S. GOV'T; TOLBUTAMIDE;

EID: 0023884027     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00614553     Document Type: Article

References (50)

1. Partial purification of human liver cytochrome P-450
2. Purification and characterisation of six cytochrome P-450 isozymes from human liver microsomes
3. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin-o-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
4. In vitro inhibition studies of two isozymes of human liver cytochrome P-450
5. Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes
6. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
7. Polymorphism of human cytochrome P-450
8. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes
9. Genetic variation in the human hepatic cytochrome P-450 system
10. In vitro evidence that tolbutamide is hydroxylated by the same human cytochrome P-450 form responsible for mephenytoin 4-hydroxylation
11. Polymorphic hydroxylation of debrisoquin in man
12. Defective oxidation of drugs: Pharmacokinetic and therapeutic implications
13. Theophylline metabolism in relation to antipyrine, debrisoquine and sparteine metabolism
14. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
15. Polymorphic metabolism of mephenytoin in man. Pharmacokinetic interaction with a co-regulated substrate, mephobarbitol
16. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers
17. Hydroxylation of desmethylimipramine. Dependence on the debrisoquin hydroxylation phenotype
18. Assessment of the drug metabolism capacity of the liver
19. Clinical assessment of enzyme induction and enzyme inhibition
20. Differential effects of enzyme induction on antipyrine metabolite formation
21. Interindividual variations in drug disposition — clinical implications and methods of investigation
22. Effect of chloroquine and primaquine on antipyrine metabolism
23. Sulfamethizole-induced inhibition of diphenylhydantion, tolbutamide and warfarin metabolism
24. The effect of sulphinpyrazone on oxidative drug metabolism in man. Inhibition of tolbutamide elimination
25. The effect of cimetidine on tolbutamide kinetics
26. Inhibition of tolbutamide elimination of cimetidine but not ranitidine
27. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man
28. Sulphaphenazole induced hypoglycaemic attacks in tolbutamide treated diabetics
29. Abbauhemmung von Tolbutamid durch Sulfaphenazol beim Menschen
30. Kinetics of drug-drug interactions
31. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulphaphenazole
32. Sulphaphenazole and drug oxidation in man
33. Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat
34. Tolbutamide 4-hydroxylase activity of human liver microsomes. Effect of inhibitors
35. Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat
36. In vitro effects of quinoline derivatives on cytochrome P-450 and aminoyprine N-demethylase activity in rat hepatic microsomes
37. Inhibition of rat hepatic mixed function oxidases by the antimalarial drugs: Selectivity for cytochromes P-450 and P-448
38. The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes
39. Effect of mefloquine on hepatic drug metabolism in the rat. Comparative study with primaquine
40. Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro
41. The effect of spironolactone on antipyrine metabolism in man
42. Comparison of the in vivo rates of formation of the three main oxidative metabolites of antipyrine in man
43. Effects of cimetidine and ranitidine on hepatic drug metabolism
44. Time course of phenobarbitone and cimetidine mediated changes in hepatic drug metabolism
45. Factors affecting the response to inhibition of drug metabolism by cimetidine-dose response and sensitivity of elderly and induced subjects
46. Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites
47. Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine
48. Influence of cimetidine on steady-state concentration and metabolite formation from antipyrine infused with a rectal osmotic mini pump
49. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat
50. Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: An alternative approach to metabolic correlation studies